Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Holdings Lifted by Bleakley Financial Group LLC

Bleakley Financial Group LLC grew its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 250.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,993 shares of the company’s stock after buying an additional 28,589 shares during the period. Bleakley Financial Group LLC’s holdings in Compass Therapeutics were worth $58,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in CMPX. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth about $25,000. Intech Investment Management LLC acquired a new position in Compass Therapeutics in the 3rd quarter valued at approximately $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at approximately $37,000. SG Americas Securities LLC grew its stake in shares of Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

CMPX has been the topic of a number of research analyst reports. Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.17.

Compass Therapeutics Stock Up 2.7 %

CMPX stock opened at $3.75 on Thursday. The company has a market cap of $515.96 million, a P/E ratio of -10.13 and a beta of 1.17. Compass Therapeutics, Inc. has a twelve month low of $0.76 and a twelve month high of $4.08. The business’s fifty day moving average is $2.20 and its 200-day moving average is $1.77.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Research analysts anticipate that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.